Stay updated with breaking news from Diagnostic Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The potential of MCED testing to reduce health inequities and an examination of accessibility, including FDA approval, physician education, patient awareness, affordability, and logistical support.
Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer's Disease International Conference -- Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer's Disease by Identifying Patients Early in the Disease Process -- News provided by Share this article Share this article MILAN, Dec. 11, 2020 /PRNewswire/ -- Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer's disease (AD), today reported that it hosted a Symposium on its prognostic biomarker test at the 34 th A...